Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase an aggregate of 7,350 shares of the Company’s common stock with an exercise price of $6.76, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on January 2, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on January 2, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
[email protected]

Media Contact:
David Rosen
Argot Partners
[email protected]

You May Also Be Interested In

• MoonExe is Proud to be a Gold Sponsor and Participant of the Malaysia Blockchain Week 2026
• Sentinel Net Lease Announces Final Closing of Sentinel Opportunity Fund I
• Bitcoin Price Prediction 2030: BTC Clears $72,903 While $BULLSKI Holds $0.000015